Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2014	2,208,953
Balance at Dec. 31, 2014	$ 2,209	$ 21,813,635	$ (35,433,396)	$ (13,617,552)
Issuance of restricted stock (in shares)	18,412
Issuance of restricted stock	$ 18	(18)
Conversion of convertible notes (in shares)	5,891,574
Conversion of convertible debt	$ 5,892	19,695,084		19,700,976
Stock-based compensation expense		594,175		594,175
Net loss			(6,719,222)	(6,719,222)
Balance (in shares) at Dec. 31, 2015	8,118,939
Balance at Dec. 31, 2015	$ 8,119	42,102,876	(42,152,618)	$ (41,623)
Conversion of convertible notes (in shares)	217,122			217,122
Conversion of convertible debt	$ 217	711,278		$ 711,495
Stock-based compensation expense		1,391,068		1,391,068
Net loss			(18,036,619)	(18,036,619)
Balance (in shares) at Dec. 31, 2016	10,345,637
Balance at Dec. 31, 2016	$ 10,346	69,363,575	$ (60,189,237)	$ 9,184,684
Fair value of RestorGenex shares (in shares)	1,861,503			1,861,503
Fair value of RestorGenex shares	$ 1,862	19,544,138		$ 19,546,000
Estimated fair value of RestorGenex stock options outstanding		1,321,000		1,321,000
Estimated fair value of RestorGenex warrants outstanding		384,000		$ 384,000
Stock Issued During Period, Shares, Issued for Services	148,073			45,643
Stock Issued During Period, Value, Issued for Services	$ 148	1,409,215		$ 1,409,363
Settlement of litigation matter upon issuance of convertible debt		$ 2,500,000		$ 2,500,000